EE200300284A - NMDA-retseptori agonisti farmatseutilised kompositsioonid - Google Patents

NMDA-retseptori agonisti farmatseutilised kompositsioonid

Info

Publication number
EE200300284A
EE200300284A EEP200300284A EEP200300284A EE200300284A EE 200300284 A EE200300284 A EE 200300284A EE P200300284 A EEP200300284 A EE P200300284A EE P200300284 A EEP200300284 A EE P200300284A EE 200300284 A EE200300284 A EE 200300284A
Authority
EE
Estonia
Prior art keywords
pharmaceutical compositions
receptor agonist
nmda receptor
nmda
agonist
Prior art date
Application number
EEP200300284A
Other languages
English (en)
Inventor
Hong Jinyang
Kim Yesook
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of EE200300284A publication Critical patent/EE200300284A/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP200300284A 2000-12-13 2001-12-05 NMDA-retseptori agonisti farmatseutilised kompositsioonid EE200300284A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25537200P 2000-12-13 2000-12-13
PCT/IB2001/002359 WO2002047685A2 (en) 2000-12-13 2001-12-05 Nmda receptor agonist pharmaceutical compositions

Publications (1)

Publication Number Publication Date
EE200300284A true EE200300284A (et) 2003-10-15

Family

ID=22968017

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300284A EE200300284A (et) 2000-12-13 2001-12-05 NMDA-retseptori agonisti farmatseutilised kompositsioonid

Country Status (42)

Country Link
US (2) US6635270B2 (et)
EP (1) EP1347760B1 (et)
JP (1) JP2004515529A (et)
KR (1) KR100533407B1 (et)
CN (1) CN1273135C (et)
AP (1) AP1235A (et)
AR (1) AR035607A1 (et)
AT (1) ATE296629T1 (et)
AU (2) AU2002218454B2 (et)
BG (1) BG107788A (et)
BR (1) BR0116085A (et)
CA (1) CA2431172A1 (et)
CZ (1) CZ20031543A3 (et)
DE (1) DE60111265T2 (et)
DO (1) DOP2001000300A (et)
DZ (1) DZ3484A1 (et)
EA (1) EA006489B1 (et)
EC (1) ECSP034655A (et)
EE (1) EE200300284A (et)
ES (1) ES2239648T3 (et)
GE (1) GEP20053568B (et)
HK (1) HK1059575A1 (et)
HR (1) HRP20030473A2 (et)
HU (1) HUP0400645A2 (et)
IL (1) IL155810A0 (et)
IS (1) IS6811A (et)
MA (1) MA26970A1 (et)
MX (1) MXPA03005257A (et)
NO (1) NO20032678L (et)
NZ (1) NZ525742A (et)
OA (1) OA12414A (et)
PA (1) PA8534901A1 (et)
PE (1) PE20020710A1 (et)
PL (1) PL362080A1 (et)
PT (1) PT1347760E (et)
SK (1) SK6982003A3 (et)
TN (1) TNSN01173A1 (et)
UA (1) UA73619C2 (et)
UY (1) UY27068A1 (et)
WO (1) WO2002047685A2 (et)
YU (1) YU41103A (et)
ZA (1) ZA200303892B (et)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1615646E (pt) 2003-04-08 2015-02-12 Progenics Pharm Inc Formulações farmacêuticas com metilnaltrexona
TW200800959A (en) * 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
TW200808740A (en) * 2006-06-09 2008-02-16 Wyeth Corp Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof
TW200811144A (en) * 2006-06-09 2008-03-01 Wyeth Corp Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline
TW200808741A (en) * 2006-06-09 2008-02-16 Wyeth Corp 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts
TW200831096A (en) * 2006-11-28 2008-08-01 Wyeth Corp Metabolites of 5-Fluoro-8-{4-[4-(6-methoxyquinolin-8-yl)piperazin-1-yl]piperidin-1-yl} quinoline and methods of preparation and uses thereof
CL2008000119A1 (es) * 2007-01-16 2008-05-16 Wyeth Corp Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia.
CN101317844B (zh) * 2007-06-08 2010-11-17 章劲夫 化合物(+)-5-甲基-10，11-二氢-5H-二苯并〔a，d〕环庚烯-5，10-亚胺在制备避孕药物中的应用
EP2331571B1 (en) 2008-09-18 2015-08-26 Northwestern University Nmda receptor modulators and uses thereof
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
SG10201811584RA (en) 2010-02-11 2019-01-30 Univ Northwestern Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof
CN102586243A (zh) * 2012-03-08 2012-07-18 中国人民解放军军事医学科学院放射与辐射医学研究所 一种预防电磁辐射致脑损伤的标志物
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
AU2014212501A1 (en) 2013-01-29 2015-07-30 Aptinyx, Inc. Spiro-lactam NMDA receptor modulators and uses thereof
HUE043843T2 (hu) 2013-01-29 2019-09-30 Aptinyx Inc Spiro-laktám NMDA receptor modulátorok és azok alkalmazása
EA201591404A1 (ru) 2013-01-29 2016-01-29 Аптиникс Инк. Спиролактамные модуляторы рецептора nmda и их применение
CA2898863A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
AU2014212485C1 (en) 2013-01-29 2018-10-25 Aptinyx, Inc. Spiro-lactam NMDA receptor modulators and uses thereof
EP3087987A4 (en) 2013-12-23 2017-08-02 Samyang Biopharmaceuticals Corporation Pharmaceutical composition containing palonosetron
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CA3024606C (en) 2016-05-19 2019-09-03 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
BR112019001926A2 (pt) 2016-08-01 2019-08-06 Aptinyx Inc moduladores do receptor nmda espiro-lactama e bis-espiro-lactama e usos destes
BR112019001768A2 (pt) 2016-08-01 2019-06-11 Aptinyx Inc moduladores do receptor de spiro-lactamas nmda e usos dos mesmos
CA3031534C (en) 2016-08-01 2023-10-17 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
JP7032378B2 (ja) 2016-08-01 2022-03-08 アプティニックス インコーポレイテッド スピロ－ラクタムｎｍｄａ受容体修飾因子及びその使用
EP3490990B1 (en) 2016-08-01 2023-12-06 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam nmda modulators and methods of using same
WO2019152687A1 (en) 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272160A (en) * 1989-05-17 1993-12-21 Pfizer Inc 2-piperidino-1-alkanol derivatives as antiischemic agents
US5710168A (en) 1991-10-23 1998-01-20 Pfizer Inc. 2-piperidino-1-alkanol derivatives as neuroprotective agents
UA59341C2 (uk) * 1995-08-11 2003-09-15 Пфайзер, Інк. (1s,2s)-1-(4-гідроксифеніл)-2-(4-гідрокси-4-фенілпіперидин-1-іл)-1-пропанолметансульфонат тригідрат
TW450807B (en) * 1995-09-15 2001-08-21 Pfizer Pharmaceutical compositions for treating tinnitus comprising neuroprotective agents

Also Published As

Publication number Publication date
US6635270B2 (en) 2003-10-21
BG107788A (bg) 2004-01-30
WO2002047685A3 (en) 2002-08-15
UA73619C2 (en) 2005-08-15
MXPA03005257A (es) 2003-09-25
IS6811A (is) 2003-05-08
OA12414A (en) 2006-04-18
AU2002218454B2 (en) 2005-10-27
HUP0400645A2 (hu) 2004-06-28
CN1479617A (zh) 2004-03-03
SK6982003A3 (en) 2004-08-03
KR20030070060A (ko) 2003-08-27
DOP2001000300A (es) 2002-05-30
YU41103A (sh) 2006-05-25
HK1059575A1 (en) 2004-07-09
DZ3484A1 (fr) 2002-06-20
US20040039022A1 (en) 2004-02-26
NZ525742A (en) 2005-07-29
CA2431172A1 (en) 2002-06-20
NO20032678D0 (no) 2003-06-12
PT1347760E (pt) 2005-09-30
AR035607A1 (es) 2004-06-16
ES2239648T3 (es) 2005-10-01
BR0116085A (pt) 2003-12-23
US20020111366A1 (en) 2002-08-15
CZ20031543A3 (cs) 2004-06-16
JP2004515529A (ja) 2004-05-27
PE20020710A1 (es) 2002-08-09
ECSP034655A (es) 2003-07-25
EP1347760A2 (en) 2003-10-01
MA26970A1 (fr) 2004-12-20
WO2002047685A2 (en) 2002-06-20
KR100533407B1 (ko) 2005-12-02
AP1235A (en) 2004-01-06
ATE296629T1 (de) 2005-06-15
AP2001002376A0 (en) 2001-12-31
GEP20053568B (en) 2005-07-11
DE60111265T2 (de) 2006-05-04
NO20032678L (no) 2003-06-12
ZA200303892B (en) 2004-05-20
TNSN01173A1 (fr) 2005-11-10
CN1273135C (zh) 2006-09-06
IL155810A0 (en) 2003-12-23
HRP20030473A2 (en) 2005-04-30
AU1845402A (en) 2002-06-24
UY27068A1 (es) 2002-07-31
DE60111265D1 (de) 2005-07-07
PL362080A1 (en) 2004-10-18
EA006489B1 (ru) 2005-12-29
EP1347760B1 (en) 2005-06-01
EA200300514A1 (ru) 2003-10-30
PA8534901A1 (es) 2002-08-26

Similar Documents

Publication Publication Date Title
EE200300284A (et) NMDA-retseptori agonisti farmatseutilised kompositsioonid
FR2795324B1 (fr) Compositions pharmaceutiques stabilisees
AR028204A1 (es) Composiciones farmaceuticas electrohiladas
IS2991B (is) Lyfjafræðileg nanóagna samsetning takykínín viðtakamótlyfs
EE200200437A (et) Manipuleerimiskindlad peroraalsed opioidagonisti preparaadid
PL365377A1 (en) Amide derivatives as nmda receptor antagonists
DK1446379T3 (da) Arylanilin-beta2-adrenergiske receptoragonister
DK1524266T3 (da) Farmaceutisk sammensætning
EG24194A (en) 5ht-a-partial agonist pharmaceutical compositions
HK1069111A1 (en) Pharmaceutical composition comprising a 5ht1 receptor agonist.
EE200300589A (et) Ravimkoostised
NO20026123L (no) Farmasöytiske sammensetninger
MA26890A1 (fr) Metabolites agonistes/ antagonistes d'oestrogenes
NO20031095L (no) Farmasoytiske sammensetninger
DK1347760T3 (da) Farmaceutiske kompositioner med NMDA receptor agonister
EE200200689A (et) Ravimkoostised
DK1450770T3 (da) Farmaceutisk præparat, der omfatter en 5HT1-receptoragonist